AMR knowledge and dispensing practices among pharmacists

Last registered on July 01, 2024
View Trial History

Pre-Trial

Trial Information

General Information

Title
AMR knowledge and dispensing practices among pharmacists
RCT ID
AEARCTR-0013911
Initial registration date
June 28, 2024

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
July 01, 2024, 12:33 PM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Name
Jan Priebe
Affiliation
Bernhard Nocht Institute for Tropical Medicine (BNITM)
Contact Primary Investigator

Other Primary Investigator(s)

PI Name
Edward Asiedu
PI Affiliation
University of Ghana
Contact Investigator
PI Name
Christoph Strupat
PI Affiliation
German Institute of Development and Sustainability (IDOS)
Contact Investigator
PI Name
Matthias Rieger
PI Affiliation
Erasmus School of Health Policy & Management
Contact Investigator

Additional Trial Information

Status
In development
Start date
2024-07-02
End date
2025-04-15
Keywords
Health
Additional Keywords
health care, pharmacy, information, Africa
JEL code(s)
D81, D83, I12
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
Our study aims to assess the impact of information on antibiotic dispensing behavior among pharmacists in urban Ghana. A focus of the study will be to understand whether optimal dispensing behaviors can be improved with a light-touch information intervention.
External Link(s)

Registration Citation

Citation
Asiedu, Edward et al. 2024. "AMR knowledge and dispensing practices among pharmacists." AEA RCT Registry. July 01. https://doi.org/10.1257/rct.13911-1.0
Sponsors & Partners
Experimental Details

Interventions

Intervention(s)
• Main treatment arm: Individuals will receive the following
o 1h in-person training session on optimal antibiotic dispensing practices
o Enrollment into a Whatsapp-based information channel that disseminates AMR information and quizzes
• Sub-treatment arms: The main treatment arm is divided into 2 groups. Group 1 receives no financial incentives for quizzes and AMR knowledge improvements while Group 2 receives small financial incentives tied to the performance in AMR quizzes.
Intervention Start Date
2024-09-01
Intervention End Date
2024-10-15

Primary Outcomes

Primary Outcomes (end points)
I) Decision to give and sell antibiotics to patient (binary indicator)
II) Quality of advice related to antibiotics and condition

Primary Outcomes (explanation)
Quality score and binary indicators related to (i) antibiotic dispensing practices and (ii) health condition behavior & monitoring

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
The study involves a clustered RCT with 1 control and 1 treatment arm. The treatment arm is further equally divided into sub-treatment arms. Clustering is at the level of micro-locations.
Experimental Design Details
Not available
Randomization Method
The random assignment will be done by the principal investigators (STATA).
Randomization Unit
Micro-locations (sub-divisions of urban communities).
Was the treatment clustered?
Yes

Experiment Characteristics

Sample size: planned number of clusters
100 micro-locations
Sample size: planned number of observations
400 at the pharmacy level and 1600 at the pharmacy-visit level (4 mystery shopper visits per pharmacy)
Sample size (or number of clusters) by treatment arms
50 micro-locations per treatment arm. Regarding sub-treatment arms the number of clusters is half (25 micro-locations per sub-treatment arm)
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
• Comparison across alternative diagnostic uncertainties: In a basic group means comparison with 80% power, a significance level of 0.05, and 0.8 unit standard deviations, the MDE is 24pp for the total sample of 400 observations (1 per pharmacy). (Assumption: Baseline mean of 0.3 & 1 treatment vs. 1 control group comparison).
Supporting Documents and Materials
IRB

Institutional Review Boards (IRBs)

IRB Name
University of Ghana
IRB Approval Date
2024-06-21
IRB Approval Number
ECH 259/ 23-24
Analysis Plan

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information